Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia
Article first published online: 7 JUN 2005
Alimentary Pharmacology & Therapeutics
Volume 21, Issue Supplement s2, pages 37–41, June 2005
How to Cite
Kinoshita, Y., Hashimoto, T., Kawamura, A., Yuki, M., Amano, K., Sato, H., Adachi, K., Sato, S., Oshima, N., Takashima, T., Kitajima, N., Abe, K. and Suetsugu, H. (2005), Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Alimentary Pharmacology & Therapeutics, 21: 37–41. doi: 10.1111/j.1365-2036.2005.02472.x
- Issue published online: 7 JUN 2005
- Article first published online: 7 JUN 2005
- Accepted for publication 13 March 2005
Background : An effective therapeutic strategy for functional dyspepsia (FD) has not been well-established.
Aim : We investigated and compared the therapeutic effects of famotidine, mosapride and tandospirone for the control of dyspeptic symptoms.
Methods : Fully examined FD patients of outpatient clinics at seven different medical centres were enrolled in the study. They were randomly assigned to three groups based on the type of drug administered: famotidine, mosapride and tandospirone. The effects of treatment over 4 weeks were assessed by visual analogue scales.
Results : All of the drugs showed beneficial effects, although famotidine was the most effective for symptom relief, which was significantly greater than tandospirone, while the effect of mosapride was similar to that of famotidine. No subtype of FD showed a better response to a particular type of drug.
Conclusions : For the treatment of FD, famotidine demonstrated the best therapeutic effect, followed by mosapride, while that of tandospirone was significantly lower.